title: Second meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Part II: benzodiazepine withdrawal.
abstract: The aim of this meeting was to describe the news trends about abuse and addiction of anxiolytics and hypnotics. The part II of this meeting reviewed several aspects of the withdrawing benzodiazepines focusing in particular on clinical symptoms, biological patterns, and strategies for discontinuation. The discontinuation is usually beneficial due to the importance of adverse effects induced by long-term use of benzodiazepines. Several clinicals options have been described including gradual tapering of the current benzodiazepine, substitution with a long acting benzodiazepines or treating the symptoms of withdrawal. Psychological interventions range from a simple support through counselling to expert cognitive-behavioural therapy. However more controlled clinical trials are needed to promote adequate and optimal patient care in management of benzodiazepine withdrawing.
authors.affiliation: CEIP associé, Service de Pharmacologie, CHU Clermont-Ferrand, Clermont-Ferrand, France. authier@hotmail.com
authors.forename: Nicolas
authors.initials: N
authors.lastname: Authier
authors.forename: Alexandra
authors.initials: A
authors.lastname: Boucher
authors.forename: Dominique
authors.initials: D
authors.lastname: Lamaison
authors.forename: Pierre-Michel
authors.initials: PM
authors.lastname: Llorca
authors.forename: Jacques
authors.initials: J
authors.lastname: Descotes
authors.forename: Alain
authors.initials: A
authors.lastname: Eschalier
mesh_terms: D001569:Benzodiazepines / Q000009:adverse effects*; D005602:France; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D019966:Substance-Related Disorders / Q000628:therapy
chemical_list: D006993:Hypnotics and Sedatives; D001569:Benzodiazepines